These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 24871583)

  • 1. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor.
    Abu El-Asrar AM; Nawaz MI; De Hertogh G; Al-Kharashi AS; Van den Eynde K; Mohammad G; Geboes K
    Curr Eye Res; 2015 Mar; 40(3):321-31. PubMed ID: 24871583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Nawaz MI; Ola MS; De Hertogh G; Opdenakker G; Geboes K
    Acta Ophthalmol; 2013 May; 91(3):e169-77. PubMed ID: 23387388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-mobility group box-1 and endothelial cell angiogenic markers in the vitreous from patients with proliferative diabetic retinopathy.
    Abu El-Asrar AM; Nawaz MI; Kangave D; Abouammoh M; Mohammad G
    Mediators Inflamm; 2012; 2012():697489. PubMed ID: 23118492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Mohammad G; Allegaert E; Ahmad A; Siddiquei MM; Alam K; Gikandi PW; De Hertogh G; Opdenakker G
    Mol Vis; 2018; 24():394-406. PubMed ID: 29853773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.
    Watanabe D; Suzuma K; Suzuma I; Ohashi H; Ojima T; Kurimoto M; Murakami T; Kimura T; Takagi H
    Am J Ophthalmol; 2005 Mar; 139(3):476-81. PubMed ID: 15767056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CORRELATION OF INCREASED INTRAVITREOUS WNT3A WITH VASCULAR ENDOTHELIAL GROWTH FACTOR IN PROLIFERATIVE DIABETIC RETINOPATHY.
    Gao X; Ma K; Lu N; Hong T; Xu Y; Peng X
    Retina; 2016 Apr; 36(4):812-8. PubMed ID: 26418446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitreous levels of placental growth factor correlate with activity of proliferative diabetic retinopathy and are not influenced by bevacizumab treatment.
    Al Kahtani E; Xu Z; Al Rashaed S; Wu L; Mahale A; Tian J; Abboud EB; Ghazi NG; Kozak I; Gupta V; Arevalo JF; Duh EJ
    Eye (Lond); 2017 Apr; 31(4):529-536. PubMed ID: 27886182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atrial natriuretic peptide in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy.
    Rollin R; Mediero A; Martínez-Montero JC; Roldán-Pallarés M; Suárez-Leoz M; Vidal-Fernández P; Cortés-Valdés C; Fernández-Cruz A; Fernández-Durango R
    Mol Vis; 2004 Jul; 10():450-7. PubMed ID: 15273657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of 150-kDa oxygen-regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Ahmad A; Alam K; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
    Acta Ophthalmol; 2018 Jun; 96(4):e460-e467. PubMed ID: 29098793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy.
    Abu El-Asrar AM; Struyf S; Mohammad G; Gouwy M; Rytinx P; Siddiquei MM; Hernández C; Alam K; Mousa A; De Hertogh G; Opdenakker G; Simó R
    Invest Ophthalmol Vis Sci; 2017 Jun; 58(7):3189-3201. PubMed ID: 28654984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis.
    Abu El-Asrar AM; Nawaz MI; De Hertogh G; Alam K; Siddiquei MM; Van den Eynde K; Mousa A; Mohammad G; Geboes K; Opdenakker G
    Mol Vis; 2014; 20():1209-24. PubMed ID: 25253987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Ahmad A; Bittoun E; Siddiquei MM; Mohammad G; Mousa A; De Hertogh G; Opdenakker G
    Acta Ophthalmol; 2018 Feb; 96(1):e27-e37. PubMed ID: 28391660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tumor necrosis factor superfamily members TWEAK, TNFSF15 and fibroblast growth factor-inducible protein 14 are upregulated in proliferative diabetic retinopathy.
    Abu El-Asrar AM; De Hertogh G; Nawaz MI; Siddiquei MM; Van den Eynde K; Mohammad G; Opdenakker G; Geboes K
    Ophthalmic Res; 2015; 53(3):122-30. PubMed ID: 25676319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of angiopoietin-like protein 8 correlates with VEGF in patients with proliferative diabetic retinopathy.
    Lu Q; Lu L; Chen W; Lu P
    Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1515-1523. PubMed ID: 28456825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
    Wang X; Wang G; Wang Y
    Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated LRP6 levels correlate with vascular endothelial growth factor in the vitreous of proliferative diabetic retinopathy.
    Gao X; Ma K; Lu N; Xu Y; Hong T; Peng X
    Mol Vis; 2015; 21():665-72. PubMed ID: 26120271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tenascin-C promotes angiogenesis in fibrovascular membranes in eyes with proliferative diabetic retinopathy.
    Kobayashi Y; Yoshida S; Zhou Y; Nakama T; Ishikawa K; Arima M; Nakao S; Sassa Y; Takeda A; Hisatomi T; Ikeda Y; Matsuda A; Sonoda KH; Ishibashi T
    Mol Vis; 2016; 22():436-45. PubMed ID: 27186070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy.
    Matsunaga N; Chikaraishi Y; Izuta H; Ogata N; Shimazawa M; Matsumura M; Hara H
    Ophthalmology; 2008 Nov; 115(11):1916-22. PubMed ID: 18718666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of stromal cell-derived factor-1 in diabetic retinopathy.
    Chen LY; Zhuo YH; Li YH; Huang XH; Zhang JL; Li SY; Wang XG; Lü L
    Chin Med J (Engl); 2010 Apr; 123(8):984-8. PubMed ID: 20497701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy.
    Abu El-Asrar AM; Siddiquei MM; Nawaz MI; De Hertogh G; Mohammad G; Alam K; Mousa A; Opdenakker G
    Mol Vis; 2016; 22():424-35. PubMed ID: 27168718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.